What is HC Wainwright’s Estimate for SCTX FY2026 Earnings?

Scribe Therapeutics Inc. (NASDAQ:SCTX – Free Report) – Research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Scribe Therapeutics in a report released on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($4.60) per share for the year, down from their previous estimate of ($3.68). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Scribe Therapeutics’ current full-year earnings is ($4.60) per share. HC Wainwright also issued estimates for Scribe Therapeutics’ Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.71) EPS, Q4 2027 earnings at ($0.80) EPS and FY2027 earnings at ($2.71) EPS.

Several other equities analysts have also recently weighed in on SCTX. Weiss Ratings initiated coverage on shares of Scribe Therapeutics in a research note on Tuesday, October 20th. They issued a “sell (e-)” rating for the company. Zacks Research raised shares of Scribe Therapeutics to a “hold” rating in a research report on Tuesday, September 1st. Wells Fargo & Company began coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They issued an “overweight” rating and a $60.00 price target for the company. Guggenheim assumed coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wall Street Zen raised shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Scribe Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $51.75.

Check Out Our Latest Stock Report on Scribe Therapeutics

Scribe Therapeutics Trading Down 10.9%

Shares of Scribe Therapeutics stock opened at $14.05 on Tuesday. Scribe Therapeutics has a 12-month low of $13.50 and a 12-month high of $39.60. The business’s 50 day moving average is $20.24.

Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The business had revenue of $1.64 million during the quarter.

Institutional Trading of Scribe Therapeutics

A number of hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. bought a new position in shares of Scribe Therapeutics during the 3rd quarter worth approximately $33,169,000. Baker BROS. Advisors LP acquired a new position in shares of Scribe Therapeutics during the 3rd quarter worth approximately $12,675,000. State Street Corp bought a new stake in Scribe Therapeutics in the 3rd quarter valued at $3,150,000. Finally, Goldman Sachs Group Inc. bought a new stake in Scribe Therapeutics in the 3rd quarter valued at $398,000.

Scribe Therapeutics News Summary

These are some of the SCTX news items that stood out recently:

  • Positive Sentiment: At the AHA Scientific Sessions, Scribe said a single dose of its STX-1150 prototype reduced LDL cholesterol by more than 50% for at least two years in non-human primates; repeat dosing lowered it further and was reported as tolerable. A surrogate for STX-1200 reduced Lp(a) by more than 95% in primates, with no detectable off-target editing in primary human liver cells. These results could support long-acting treatments, although the evidence remains preclinical. Company announcement
  • Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including reducing its FY2026 estimate to a loss of $4.60 per share from $3.68 and its FY2027 estimate to a loss of $2.71 from $2.52. The firm maintained its Buy rating and $60 target, but the forecast cuts may add pressure to sentiment. Analyst estimate report

Scribe Therapeutics Company Profile

(Get Free Report)

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.

Read More

Earnings History and Estimates for Scribe Therapeutics (NASDAQ:SCTX)

Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.